Barclays PLC Ionis Pharmaceuticals Inc Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Barclays PLC holds 100,000 shares of IONS stock, worth $3.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

100,000

Previous 100,000 -0.0%

Holding current value

$3.4 Million

Previous $4.01 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$40.06 - $51.86 $855,601 - $1.11 Million	21,358 Added 3.47%	637,032 $25.5 Million
Q2 2024 Aug 14, 2024	BUY	$36.45 - $47.7 $1.4 Million - $1.83 Million	38,287 Added 6.63%	615,674 $29.3 Million
Q1 2024 May 15, 2024	SELL	$42.03 - $53.55 $2.82 Million - $3.59 Million	-67,121 Reduced 10.41%	577,387 $25 Million
Q4 2023 Feb 15, 2024	BUY	$43.39 - $51.63 $214,997 - $255,826	4,955 Added 0.77%	644,508 $32.6 Million
Q3 2023 Nov 07, 2023	BUY	$38.5 - $47.13 $3.75 Million - $4.59 Million	97,321 Added 17.95%	639,553 $29 Million
Q2 2023 Aug 03, 2023	BUY	$34.73 - $43.33 $2.9 Million - $3.61 Million	83,415 Added 18.18%	542,232 $22.2 Million
Q1 2023 May 04, 2023	SELL	$33.58 - $41.2 $1.63 Million - $2 Million	-48,494 Reduced 9.56%	458,817 $16.4 Million
Q4 2022 Feb 13, 2023	BUY	$37.12 - $46.52 $104,789 - $131,325	2,823 Added 0.56%	507,311 $19.2 Million
Q3 2022 Nov 03, 2022	BUY	$36.54 - $48.66 $5.48 Million - $7.29 Million	149,909 Added 42.28%	504,488 $22.3 Million
Q2 2022 Aug 12, 2022	BUY	$31.71 - $43.0 $1.21 Million - $1.64 Million	38,229 Added 12.08%	354,579 $13.1 Million
Q1 2022 May 16, 2022	SELL	$29.88 - $37.04 $406,009 - $503,299	-13,588 Reduced 4.12%	316,350 $11.7 Million
Q4 2021 Feb 14, 2022	SELL	$25.61 - $35.1 $9,040 - $12,390	-353 Reduced 0.11%	329,938 $10 Million
Q3 2021 Nov 09, 2021	SELL	$33.54 - $40.55 $1.13 Million - $1.37 Million	-33,705 Reduced 9.26%	330,291 $11.1 Million
Q2 2021 Aug 13, 2021	BUY	$34.54 - $47.25 $9.16 Million - $12.5 Million	265,225 Added 268.53%	363,996 $14.5 Million
Q1 2021 May 13, 2021	BUY	$42.51 - $63.78 $1.24 Million - $1.86 Million	29,106 Added 41.78%	98,771 $4.44 Million
Q4 2020 Feb 11, 2021	SELL	$45.3 - $60.27 $280,044 - $372,589	-6,182 Reduced 8.15%	69,665 $3.94 Million
Q3 2020 Nov 12, 2020	SELL	$47.45 - $62.95 $187,617 - $248,904	-3,954 Reduced 4.95%	75,847 $3.6 Million
Q2 2020 Aug 12, 2020	BUY	$46.85 - $61.05 $795,466 - $1.04 Million	16,979 Added 27.03%	79,801 $4.71 Million
Q1 2020 May 13, 2020	SELL	$41.6 - $63.4 $1.34 Million - $2.05 Million	-32,258 Reduced 33.93%	62,822 $2.97 Million
Q4 2019 Feb 10, 2020	BUY	$53.85 - $65.27 $2.2 Million - $2.67 Million	40,921 Added 75.56%	95,080 $5.74 Million
Q3 2019 Nov 14, 2019	SELL	$59.06 - $72.15 $12.1 Million - $14.8 Million	-204,634 Reduced 79.07%	54,159 $3.24 Million
Q2 2019 Aug 14, 2019	BUY	$62.09 - $86.14 $8.75 Million - $12.1 Million	140,885 Added 119.49%	258,793 $16.6 Million
Q1 2019 May 15, 2019	BUY	$52.92 - $81.17 $2.93 Million - $4.49 Million	55,351 Added 88.48%	117,908 $9.57 Million
Q4 2018 Feb 14, 2019	SELL	$43.37 - $59.54 $541,214 - $742,999	-12,479 Reduced 16.63%	62,557 $3.38 Million
Q3 2018 Nov 14, 2018	BUY	$42.88 - $53.7 $2.64 Million - $3.31 Million	61,681 Added 461.86%	75,036 $3.87 Million
Q2 2018 Aug 14, 2018	SELL	$40.53 - $50.7 $2.09 Million - $2.61 Million	-51,490 Reduced 79.4%	13,355 $556,000
Q1 2018 May 15, 2018	BUY	$44.08 - $55.05 $2.27 Million - $2.84 Million	51,577 Added 388.73%	64,845 $2.86 Million
Q4 2017 Feb 14, 2018	SELL	$50.3 - $64.39 $1.5 Million - $1.91 Million	-29,739 Reduced 69.15%	13,268 $667,000
Q3 2017 Nov 14, 2017	BUY	$45.56 - $59.57 $1.96 Million - $2.56 Million	43,007	43,007 $2.18 Million

Others Institutions Holding IONS

# of Institutions

402

Shares Held

136M

Call Options Held

862K

Put Options Held

582K

View Full List

About IONIS PHARMACEUTICALS INC

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $4.83B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

More about IONS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account